Sun, Sep 21, 2014, 4:06 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • chrisroxder chrisroxder Dec 28, 2012 8:09 PM Flag

    Wow wow wow - read the 8-k

    Wow - Anyone read the 8-k?

    "The Board authorized the adoption of a Rights Agreement in order to protect stockholders from coercive or otherwise unfair takeover tactics"

    "the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders."

    I wasn't really expecting a buyout to be honest. While GDNF was purchased during pre clinical trials for $250 Million, I'm only using that as a benchmark for valuation of AMBS. MANF is producing better results and delivery methods have improved dramatically since then. Assuming a hefty discount I still think the MANF protein, with patent protection recently upheld in court, would be worth $100 Million. Now we get news that they're instituting a Rights Agreement just ahead of the 1/8/13 presentation which will be done in front of big pharma and VC investors and one of the presenters is the co-Founder of Amgen. This is setting up for an interesting couple of weeks here to say the least.

    Again, I think this is an EPIC STOCK - one that comes around only once every 5 years or so. They go up 100 to 300 times from the bottom to the top in a 6 month period and any pullback turns into a buying opportunity. People that try to flip it end up chasing it higher with less and less shares and resort to bashing it on the grounds of phony conspiracy theories about dilutions etc...the patient ones make out like bandits.


    Wow - Anyone read the 8-k?

    "The Board authorized the adoption of a Rights Agreement in order to protect stockholders from coercive or otherwise unfair takeover tactics"

    "the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders."

    I wasn't really expecting a buyout to be honest. While GDNF was purchased during pre clinical trials for $250 Million, I'm only using that as a benchmark for valuation of AMBS. MANF is producing better results and delivery methods have improved dramatically since then. Assuming a hefty discount I still think the MANF protein, with patent protection recently upheld in court, would be worth $100 Million. Now we get news that they're instituting a Rights Agreement just ahead of the 1/8/13 presentation which will be done in front of big pharma and VC investors and one of the presenters is the co-Founder of Amgen. This is setting up for an interesting couple of weeks here to say the least.

    Again, I think this is an EPIC STOCK - one that comes around only once every 5 years or so. They go up 100 to 300 times from the bottom to the top in a 6 month period and any pullback turns into a buying opportunity. People that try to flip it end up chasing it higher with less and less shares and resort to bashing it on the grounds of phony conspiracy theories about dilutions etc...the patient ones make out like bandits.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMBS
0.0875-0.0042(-4.58%)Sep 19 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.